In 2005, the incidence of Parkinson’s disease (PD) in the world’s most populous nations was estimated to be 4.1 million people . Furthermore, it is predicted that by the year 2030 more than 8 million people in these countries will develop this disease . PD is progressive and over time symptoms can become increasingly severe. There are four cardinal symptoms including tremor at rest, rigidity, akinesia or bradykinesia and postural instability . Common treatments include pharmacological (levodopa/carbidopa, Sinemet), surgical (deep brain stimulation), and physical therapy (exercise and functional training). With this increase in the incidence of PD, additional treatment options are required to enhance the quality of life in these individuals.